drugset / Trial / NCT00395135

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

NCT00395135

Phase 3 Completed 3182 enrolled Eisai Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of treatment (Week 104)

Timeline

Start
2006-11
Primary completion
2009-02
Completion
2009-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorcaserin Small molecule 10 mg

Indications